Cargando…

Anamorelin HCl (ONO-7643), a novel ghrelin receptor agonist, for the treatment of cancer anorexia-cachexia syndrome: preclinical profile

BACKGROUND: Anamorelin HCl (ANAM) is a novel, orally active, ghrelin receptor agonist in clinical development for the treatment of cancer cachexia. We report in vitro and in vivo studies evaluating the preclinical pharmacologic profile of ANAM. METHODS: Fluorescent imaging plate reader and binding a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pietra, Claudio, Takeda, Yasuhiro, Tazawa-Ogata, Naoko, Minami, Masashi, Yuanfeng, Xia, Duus, Elizabeth Manning, Northrup, Robert
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2014
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4248409/ https://www.ncbi.nlm.nih.gov/pubmed/25267366 http://dx.doi.org/10.1007/s13539-014-0159-5

Ejemplares similares

Effect of ghrelin and anamorelin (ONO-7643), a selective ghrelin receptor agonist, on tumor growth in a lung cancer mouse xenograft model
por: Northrup, R., et al.
Publicado: (2013)

Anamorelin (ONO‐7643) for the treatment of patients with non–small cell lung cancer and cachexia: Results from a randomized, double‐blind, placebo‐controlled, multicenter study of Japanese patients (ONO‐7643‐04)
por: Katakami, Nobuyuki, et al.
Publicado: (2017)

A multicenter, open‐label, single‐arm study of anamorelin (ONO‐7643) in advanced gastrointestinal cancer patients with cancer cachexia
por: Hamauchi, Satoshi, et al.
Publicado: (2019)

Anamorelin (ONO-7643) in Japanese patients with non-small cell lung cancer and cachexia: results of a randomized phase 2 trial
por: Takayama, Koichi, et al.
Publicado: (2016)

A multicenter, open‐label, single‐arm study of anamorelin (ONO‐7643) in patients with cancer cachexia and low body mass index
por: Naito, Tateaki, et al.
Publicado: (2022)

Effects of the ghrelin receptor agonist anamorelin on lean body mass in cancer patients with cachexia; results from a Phase II randomized, double blind, multicenter study
por: Garcia, Jose M, et al.
Publicado: (2014)

Evidence for partial pharmaceutical reversal of the cancer anorexia–cachexia syndrome: the case of anamorelin
por: Anker, Stefan D, et al.
Publicado: (2015)

Anamorelin hydrochloride in the treatment of cancer anorexia–cachexia syndrome: design, development, and potential place in therapy
por: Graf, Solomon A, et al.
Publicado: (2017)

The efficacy and safety of anamorelin for patients with cancer-related anorexia/cachexia syndrome: a systematic review and meta-analysis
por: Taniguchi, Jumpei, et al.
Publicado: (2023)

Potentiation of ghrelin signaling attenuates cancer anorexia–cachexia and prolongs survival
por: Fujitsuka, N, et al.
Publicado: (2011)

Rikkunshito, a ghrelin potentiator, ameliorates anorexia–cachexia syndrome
por: Fujitsuka, Naoki, et al.
Publicado: (2014)

Plasma Ghrelin Levels Are Associated with Anorexia but Not Cachexia in Patients with NSCLC
por: Blauwhoff-Buskermolen, Susanne, et al.
Publicado: (2017)

Factors associated with early discontinuation of anamorelin in patients with cancer-associated cachexia
por: Tsukiyama, Ikuto, et al.
Publicado: (2023)

Appetite and food intake results from phase I studies of anamorelin
por: Blum, Robert A., et al.
Publicado: (2019)

Impact of the Extent of Weight Loss before Administration on the Efficacy of Anamorelin in Advanced Pancreatic Cancer Patients with Cachexia
por: Takeda, Tsuyoshi, et al.
Publicado: (2022)

Ghrelin for cachexia
por: Akamizu, Takashi, et al.
Publicado: (2010)

Efficacy of Anamorelin, a Novel Non-Peptide Ghrelin Analogue, in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) and Cachexia—Review and Expert Opinion
por: Currow, David C., et al.
Publicado: (2018)

Combination therapy with anamorelin and a myostatin inhibitor is advantageous for cancer cachexia in a mouse model
por: Hanada, Kako, et al.
Publicado: (2022)

A case of squamous cell lung cancer treated with anamorelin in combination with a multidisciplinary collaborative approach for treating cancer cachexia
por: Oshima, Yuri, et al.
Publicado: (2022)

Oncology Update: Anamorelin
por: Prommer, Eric
Publicado: (2017)

Predictors of efficacy of anamorelin in patients with non‑small cell lung cancer and cachexia: A retrospective study
por: Ishioka, Yoshiko, et al.
Publicado: (2023)

An open-label clinical trial of the effects of age and gender on the pharmacodynamics, pharmacokinetics and safety of the ghrelin receptor agonist anamorelin
por: Leese, Philip T, et al.
Publicado: (2015)

Efficacy and safety of anamorelin in patients with cancer cachexia: Post‐hoc subgroup analyses of a placebo‐controlled study
por: Takayama, Koichi, et al.
Publicado: (2022)

Chronic Renal Failure, Cachexia, and Ghrelin
por: Laviano, A., et al.
Publicado: (2010)

Novel mechanism of ghrelin therapy for cachexia
por: Hatanaka, Michiyoshi, et al.
Publicado: (2015)

The Role of Ghrelin in Anorexia Nervosa
por: Schalla, Martha A., et al.
Publicado: (2018)

Megestrol acetate in cachexia and anorexia
por: Yeh, Shing-shing, et al.
Publicado: (2006)

Leptin in Anorexia and Cachexia Syndrome
por: Engineer, Diana R., et al.
Publicado: (2012)

Cachexia-anorexia in cancer patients
Publicado: (1996)

Pathophysiology of anorexia in the cancer cachexia syndrome
por: Ezeoke, Chukwuemeka Charles, et al.
Publicado: (2015)

Refractory Monomorphic Ventricular Tachycardia Induced by Anamorelin
por: Sakagami, Hiroaki, et al.
Publicado: (2022)

Attenuation of Visceral and Somatic Nociception by Ghrelin Mimetics
por: N Mohammadi, Ehsan, et al.
Publicado: (2020)

ROMANA 3: a phase 3 safety extension study of anamorelin in advanced non-small-cell lung cancer (NSCLC) patients with cachexia
por: Currow, D., et al.
Publicado: (2017)

Cachexia: Pathophysiology and Ghrelin Liposomes for Nose-to-Brain Delivery
por: T. de Barros, Cecilia, et al.
Publicado: (2020)

Supplementary Oral Anamorelin Mitigates Anorexia and Skeletal Muscle Atrophy Induced by Gemcitabine Plus Cisplatin Systemic Chemotherapy in a Mouse Model
por: Miyake, Makito, et al.
Publicado: (2020)

Ghrelin: Central and Peripheral Implications in Anorexia Nervosa
por: Méquinion, Mathieu, et al.
Publicado: (2013)

Synthesis and Applications of (ONO Pincer)Ruthenium‐Complex‐Bound Norvalines
por: Isozaki, Katsuhiro, et al.
Publicado: (2016)

Optimal management of cancer anorexia–cachexia syndrome
por: Argilés, Josep M, et al.
Publicado: (2010)

Safety, tolerability and pharmacokinetics of intravenous ghrelin for cancer-related anorexia/cachexia: a randomised, placebo-controlled, double-blind, double-crossover study
por: Strasser, F, et al.
Publicado: (2008)

Ghrelin and its potential in the treatment of eating/wasting disorders and cachexia
por: Müller, Timo D., et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_jt7imqk6d6ghod58h3eta20u7s